Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with CancerPurpose:Experimental Design:Results:Conclusions:

Peer reviewed scientific article

Anglais

DOI : 10.1158/1078-0432.Ccr-22-2185